Get started

Stockstobuy

Results of annual general meeting declared by Universal IbogaineAround 6 million Canadians will meet addiction during their lifetime, according to the Canadian Mental Health Association. With 22,828 total fatalities in Canada over a five year period, the opioid crisis marks one of the most extreme types of addiction. The fatality rate is rising year to year. Universal Ibogaine constantly working on a mission to transform addiction treatment using ibogaine through a planned Canadian clinical trial focused on opioid use disorder. Recently universal ibogaine declared the results and Investors are very happy with the latest press release of $IBO as all resolutions were passed by the requisite majority of shareholders at its annual general meeting which was held on October 3, 2022 in Vancouver. The shareholders also approved the re-appointment of Deloitte LLP as auditors of the Company for the ensuing year, and approved the Company’s 2021 Stock Option Plan, the Company’s 2022 Equity Incentive Compensation Plan and the Company’s 2022 Stock Option Plan. TSXV:IBO universalibogaine.com/universal-ibogaine-announces-results-of-annual-general-meeting/ Universal ibogaine plans to transform addiction management, while developing ibogaine as a central component of innovation for addiction treatment. · Universal ibogine engaged in acquiring an active addiction treatment center in Canada to perfect the wrap-around treatments and roll out ibogaine once approved in Canada. Also partnering with Canadian First Nations to investigate treatment possibilities on sovereign indigenous territories. · Universal ibogaine has developed a state of the art holistic addiction treatment protocol at its Kelburn clinic that, when paired with planned ibogaine detox protocol. It is also intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. Universal ibogaine , one of the versatile bio technology companies, was created with the goal of medicalizing ibogaine for addiction treatment in Canada and then globally. TSX-V:IBO
TSXV:IBO
by Matthew-Davies1705
1
Global battery management market is expected to reach USD 5.4 B$GEMS.C – Great opportunity to capture the expanding Global battery management market. Although COVID-19 negatively impacted the global battery management market in 2020, it is expected to reach USD 5.4 billion in 2022. It is projected to register a CAGR of over 4.85% during the forecast period (2022-2027). Now the market has reached the pre-pandemic level. The battery management system is meant to track the aspects of the battery system and its cells and use the information gathered to reduce safety hazards and improve battery performance. High demand for battery management systems will accelerate the market growth of battery management systems. This is the perfect opportunity to occupy a significant market share of any lithium mining and supplying company. prnewswire.com/news-releases/global-battery-management-system-market-expected-to-reach-5-4-billion-in-2022--301658228.ht ml $GEMS.C is the leading single sources supplier of critical energy minerals used for clean and green energy evolution. As lithium is a crucial element for the battery management system, Infinity stone venture corporation continuously focuses on a smooth supply of critical energy minerals. * Investors in the Infinity stone venture get exposure to lithium, graphite, copper, cobalt, nickel, manganese, and possibly some PGMs & REEs. * Infinity's lithium mining portfolio is impressive; four projects, 11k+ hectares, 65+ pegmatites, tens of km of a prospective strike — very near or bordering Patriot Battery Metals * infinity stone venture successfully confirmed historically mapped pegmatites and identified new showings. Eighty-seven samples were collected over 3,850 hectares of claims adjacent to the Patriot discovery. $GEMS.C has a bright future in the global battery management market and is constantly fulfilling the demand for critical energy minerals through its eco-friendly mining program. It has government tax incentives and grants, including Canada's 30% Critical Mineral Flow-Through Tax Credit. (CSE: GEMS) (OTC: GEMSF)
CSE:GEMS
by Matthew-Davies1705
Will earnings Season push S&P to new lows? With the latest US earnings season underway, plenty of investors are still wary of making investment decisions. They hope that the earnings results will serve as guidance as to how the next few months will look like before factoring in fresh monetary policies and inflationary measures. Earnings and the S&P 500 In the lead up to the earnings season, A Bloomberg survey showed that more than 60% of its 724 respondents believed the third-quarter earnings season will push the S&P 500 index lower. But data from American financial data and software company FactSet is painting a different picture, revealing analysts' expectation of a roughly 7.5% growth in the earnings for S&P 500 companies for this year and the next, despite investors' fear of a worsening economic downturn. Federal Rate decision While investors are seeking clarity from the third-quarter earnings season, industry players and analysts are united in the belief that the Federal Reserve's rate decision will likely override any positive momentum and have major impact to stock performance moving forward. JPMorgan CEO Jamie Dimon said depending on whether the Federal Reserve engineers a soft or hard landing for the economy, the S&P 500 could fall another 20%. It came with a warning on Monday that the US would likely fall into a recession over the next six to nine months. In contrast, the International Monetary Fund, said Tuesday that it expects the US economy to grow 1%. The price of goods and services in the US continued to grow in September, with the consumer price index 8.2% higher than the prior-year period. The Federal Reserve and some economists maintain that demand generated by a hot labor market and higher wages fuel inflation and that higher unemployment and interest rates are the solution to bring it down. President of Yardeni Research Ed Yardeni expects the S&P 500 to wait until the end of 2023 to be back at its peak, while other analysts are betting on an improving outlook that will push stock prices higher, the New York Times reported.
SP:SPX
by BlackBull_Markets
Twitter ($TWTR) Can Rise Much Higher, Wait For A BreakoutTraders and Investors, Twitter currently is at an important structure zone. If that zone is broken and confirmed, it can rise much higher to the targets shown in the chart. Please support this analysis by liking and sharing. 👍🙂 Rules: 1. Never trade too much 2. Never trade without a confirmation 3. Never rely on signals, do your own analysis and research too ✅ If you found this idea useful, hit the like button, subscribe and share it in other trading forums. ✅ Follow me for future ideas, trade set ups and the updates of this analysis ✅ Don't hesitate to share your ideas, comments, opinions and questions. Take care and trade well -Vik ____________________________________________________ 📌 DISCLAIMER The content on this analysis is subject to change at any time without notice, and is provided for the sole purpose of education only. Not a financial advice or signal. Please make your own independent investment decisions. ____________________________________________________
NYSE:TWTRLong
by vikinsa
EVFM 53X Upside potential according to Morgan Stanley !EVFM Evofem Biosciences has a big upcoming catalyst: Its Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women is on track to report top-line data from this landmark trial in mid-October, so we are one week away from results! Positive study outcomes would enable potential U.S. approval for prevention of these sexually transmitted infections in 2023. Evofem`s Phexxi whas already approved in Nigeria, the most populous country in Africa and the seventh largest country in the world, 3 days ago. On 4/12/2022 Jeffrey Hung from Morgan Stanley Boosted the Price Target for EVFM to Underweight, from $7.95 to $8.55. On 8/15/2022 HC Wainwright Boosted the Price Target to $4.00, giving a Buy Rating. Now the stock is trading at all time low, $0.16, while 4 months ago it was trading 10X higher. In my opinion this is a premium call and a great buy opportunity ahead of a Big upcoming catalyst for EVFM Evofem Biosciences. Looking forward to read your opinion about it.
OTC:EVFMLong
by TopgOptions
1
ADBE ADD TO WATCHLIST!🔸️Ticker Symbol: ADBE🔸️Timeframe: 4 Hour🔸️Investment Strategy: Long TECHNICAL ANALYSIS: ADBE on the 4H timeframe is setting up nice to see an increase in value if we can stay in this current trend. Our white line representing money momentum on the bottom dashboard indicator is shifting to the upside and we also have a green middle band illuminated meaning bull market momentum. The final confirmation that I want to be looking out for is a green dot meaning a key ema crossover to the upside which would just give me added confirmation that taking a long position on ADBE could result in some nice gains. Thanks for following! 🔔 Follow for daily stock, crypto and forex technical analysis. ⚠️ Trading is risky and I understand nothing is guaranteed. Proper risk management should be in place at all times to minimize losses. Please consult a financial advisor before trading. All Inclusive Trading LLC is not a financial advisor and may not be held liable for any losses which may occur.
NASDAQ:ADBELong
by TrendsiTrades
AAPL: Ready For BounceTicker Symbol: $AAPL ️Timeframe: 1D Investment Strategy: LONG (SHORT TERM) REJECTION OF 50SMA AND AT SUPPORT LEVEL STOCHASTIC SHIFTING UP AND RSI OVERSOLD. Follow for daily stock, crypto and forex technical analysis. Trading is risky, and I understand nothing is guaranteed. Proper risk management should be in place at all times to minimize losses. Please consult a financial advisor before trading. All Inclusive Trading LLC is not a financial advisor and may not be held liable for any losses which may occur.
NASDAQ:AAPLLong
by Red_Green-TA
FWBI 81X Upside Potential according to this Analyst!On 5/26/2022 Roth Capital brokerage Lowered the Price Target for First Wave BioPharma, Inc. (FWBI) from $600.00 to $270.00 giving a Buy Rating for the stock! The stock is now at a historic low: $3.31. In January 2021 it was $788. Just to reach the Analyst Price Target, it need to grow 81.5X from this level. The Market cap is extremely low: 4.58 Mil. 81X would be $371 Mil. And wouldn`t be too much, if we look at their pipeline: 2 candidates reaching Phase 3 clinical trials, 3 candidates in Phase 2 and one in Phase one, in the following fields: Digestive/Nutritional Diseases, Inflammatory Diseases and Oncology. It can explode anytime. Even though the institutional ownership it`s not high, some of the shareholders that recently reported increasing stakes in the company are: Goldman Sachs, Blackrock and Jane Street Group. This one is a premium call in my opinion. Looking forward to read your opinion about it.
FLong
by TopgOptions
9